loading
Precedente Chiudi:
$0.401
Aprire:
$0.398
Volume 24 ore:
25,360
Relative Volume:
0.06
Capitalizzazione di mercato:
$1.99M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-21.85%
1M Prestazione:
-40.07%
6M Prestazione:
-85.75%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$0.3881
$0.42
Intervallo di 1 settimana:
Value
$0.38
$0.5015
Portata 52W:
Value
$0.185
$3.00

Entero Therapeutics Inc Stock (ENTO) Company Profile

Name
Nome
Entero Therapeutics Inc
Name
Telefono
561-589-7020
Name
Indirizzo
777 YAMATO ROAD, BOCA RATON
Name
Dipendente
11
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
ENTO's Discussions on Twitter

Confronta ENTO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ENTO 0.4075 1.99M 0 0 0 0.00
VRTX 450.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.53 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.84 24.89B 3.30B -501.07M 1.03B 11.54

Entero Therapeutics Inc Borsa (ENTO) Ultime notizie

pulisher
Nov 16, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders - GlobeNewswire Inc.

Nov 16, 2024
pulisher
Nov 15, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire

Nov 15, 2024
pulisher
Nov 14, 2024

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Nov 13, 2024
pulisher
Nov 13, 2024

Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian

Nov 13, 2024
pulisher
Nov 13, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve

Nov 13, 2024
pulisher
Nov 13, 2024

ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Nov 13, 2024
pulisher
Nov 13, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Entero, Journey to merge, creating oncology-focused biopharma - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com

Nov 12, 2024
pulisher
Nov 03, 2024

FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Nov 03, 2024
pulisher
Nov 02, 2024

AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com

Nov 02, 2024
pulisher
Oct 30, 2024

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com

Oct 30, 2024
pulisher
Oct 25, 2024

Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace

Oct 25, 2024
pulisher
Oct 16, 2024

How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register

Oct 16, 2024
pulisher
Oct 11, 2024

Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India

Oct 11, 2024
pulisher
Oct 09, 2024

Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex

Oct 09, 2024
pulisher
Oct 08, 2024

Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News

Oct 08, 2024
pulisher
Oct 07, 2024

Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News

Oct 07, 2024
pulisher
Oct 07, 2024

ENTO’s 2023 Market Dance: Down -85.72% – Time to Invest? - The InvestChronicle

Oct 07, 2024
pulisher
Oct 04, 2024

Lexicon Pharmaceuticals (LXRX) Stock Surges Amid Positive Analys - GuruFocus.com

Oct 04, 2024
pulisher
Sep 18, 2024

EMCOR Group (NYSE:EME) Sets New 12-Month High at $402.91 - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Evolus (NASDAQ:EOLS) Trading Down 2.9% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Health Beat: Hope for children with EoE - 69News WFMZ-TV

Sep 18, 2024
pulisher
Sep 18, 2024

Emmaus Life Sciences director buys $800 in company stock By Investing.com - Investing.com UK

Sep 18, 2024
pulisher
Sep 18, 2024

Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal

Sep 18, 2024
pulisher
Sep 16, 2024

EMCOR Group (NYSE:EME) Hits New 1-Year High at $402.91 - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 16, 2024
pulisher
Sep 13, 2024

Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga

Sep 13, 2024
pulisher
Sep 11, 2024

Entero Therapeutics faces Nasdaq delisting over share price - Investing.com

Sep 11, 2024
pulisher
Sep 11, 2024

Entero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Sep 11, 2024
pulisher
Sep 11, 2024

Canoo Inc (NASDAQ: GOEV) Could Pass $4.5 In One Year Stock Forecast - Stocks Register

Sep 11, 2024
pulisher
Sep 10, 2024

Understanding ENTO stock ratios for better investment decisions - US Post News

Sep 10, 2024
pulisher
Sep 10, 2024

Entero Therapeutics Secures Exclusive Technology License - Investing.com

Sep 10, 2024
pulisher
Sep 10, 2024

Entero Therapeutics Secures Exclusive Technology License By Investing.com - Investing.com Canada

Sep 10, 2024
pulisher
Sep 10, 2024

Entero Therapeutics signs letter of intent with Data Vault Holdings - TipRanks

Sep 10, 2024
pulisher
Sep 10, 2024

Entero Therapeutics Signs Letter of Intent to License and - GlobeNewswire

Sep 10, 2024
pulisher
Aug 29, 2024

Entero Therapeutics appoints new independent accountant - Investing.com India

Aug 29, 2024
pulisher
Aug 29, 2024

Entero Therapeutics appoints new independent accountant By Investing.com - Investing.com Canada

Aug 29, 2024
pulisher
Aug 28, 2024

Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 666.0% in August - Defense World

Aug 28, 2024

Entero Therapeutics Inc Azioni (ENTO) Dati Finanziari

Non sono disponibili dati finanziari per Entero Therapeutics Inc (ENTO). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):